Clinical Trial 23562

• Overview

  Study Title:

  A Phase II Double-Blinded, Placebo-Controlled Trial of Prostate Oligometastatic Radiotherapy with or without Androgen Deprivation Therapy in Oligometastatic Prostate Cancer (NRG Promethean)

  Objective:

  Primary Objective * Compare conventional radiological progression-free survival (rPFS) for positron emission tomography (PET)-detected, biochemically recurrent, oligometastatic, castration-sensitive prostate cancer patients treated with SABR plus placebo vs. SABR plus relugolix. Secondary Objectives * Compare conventional or PET-based radiological progression-free survival (prPFS) between treatment arms. * Compare patient-reported sexual and hormonal quality of life as assessed by corresponding EPIC-26 domains between treatment arms. * Compare other measures of quality of life obtained from the EQ5D-5L, EORTC QLQ-30, PROMIS Fatigue instruments between the two treatment arms. * Compare time to salvage therapy and time to castration-resistance between treatment arms. * Compare local progression (SABR-targeted lesion), biochemical progression, distant metastases, prostate cancer-specific mortality, metastasis-free survival, and overall survival between treatment arms. * Determine adverse events rates and compare rates between the two treatment arms.

• Treatments

  Therapies:

  Androgen deprivation therapy (ADT); Radiotherapy

  Medications:

  Placebo (); Radiotherapy (); Relugolix (Orgovyx)

• Inclusion Criteria

  Key Inclusion Criteria:
  • Pathologically (histologically or cytologically) proven diagnosis of prostate adenocarcinoma at any anatomical location (for example, prostate, metastatic site), including intraductal or ductal carcinoma, at any time before registration.
  • Age ≥ 18 years.
  • ECOG Performance Status 0-2 within 180 days prior to registration.
  • Prior curative-intent treatment to the prostate, by either: External beam and/or brachytherapy to: Prostate alone, prostate and seminal vesicles, prostate and pelvic nodes, or radiation to all three sites. Radical prostatectomy alone, radical prostatectomy plus postoperative radiotherapy to the prostate bed, or radical prostatectomy plus postoperative radiotherapy to the pelvic nodes.
  • Must meet study entry criteria based on the following diagnostic workup within 180 days prior to registration: History and physical examination; Fluciclovine or PSMA PET scan; PET must be combined with either CT or MRI, but a diagnostic CT or MRI reading/interpretation is not required.
  • 1 - 5 oligometastatic lesions in bone and/or nodal/soft tissue (non-abutting nodes are counted separately) sites on fluciclovine or PSMA PET within 180 days prior to registration and includes at least ONE of the following: Bone – each metastasis is counted (for example, 2 distinct lesions in the right ilium count as 2 oligometastatic lesions), Extrapelvic Nodal/ soft tissue – requires at least one extrapelvic inguinal or a nodal/soft tissue lesion superior to the iliac bifurcation (that is, AJCC M1a version 8).
  • Serum total prostate-specific antigen (PSA) post-RT nadir PSA + 2 ng/mL obtained within 180 days prior to registration, or PSA>0.2 ng/mL with at least two rises from post-treatment nadir with most recent PSA within 180 days prior to registration. If patient has received a radical prostatectomy with or without post-op RT, either Current PSA>0.2 ng/mL with a secondary confirmatory PSA >0.2 ng/mL with most recent PSA obtained within 180 days prior to registration, or  two consecutive PSA rises from post-operative nadir, with most recent PSA obtained within 180 days prior to registration.
  • Must have > 3 PSA values within the last two years since end of primary treatment or within the last 2 years prior to registration, whichever is less.
  • Serum total testosterone >100 ng/dL within 180 days prior to registration.
  • Adequate hepatic function within 180 days prior to registration defined as follows: Total Bilirubin: ≤ 1.5 × institutional upper limit of normal (ULN) (Note: In subjects with Gilbert’s syndrome, if total bilirubin is >1.5 × ULN, subject is eligible if direct bilirubin is ≤1.5 × ULN), and AST(SGOT) and ALT(SGPT): ≤ 2.5 × institutional ULN.
  • For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.
  • Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.
  • HIV-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial.
  • The patient must agree to use a highly effective contraception (even men with vasectomies) if he is having sex with a woman of childbearing potential or with a woman who is pregnant while on study drug and for 2 weeks following the last dose of study drug.
  • Other inclusion criteria may apply.

• Exclusion Criteria

  Key Exclusion Criteria:
  • Currently on androgen deprivation or anti-androgen therapy.
  • Spinal cord compression, or spinal intramedullary, brain, and/or visceral (for example liver etc.) metastasis.
  • Biopsy-proven prostatic carcinoma with signet-ring, sarcomatoid, or neuroendocrine features (for example, small cell).
  • Prior metastatic or non-metastatic, invasive malignancy (except non metastatic, nonmelanomatous skin cancer) unless continuously disease free for > 3 years.
  • Prior chemotherapy for prostate cancer or bilateral orchiectomy.
  • Prior high dose radiotherapy to a lesion identified in 3.1.6 (i.e. oligometastatic recurrence by PET) Note: Lesions outside of a previously irradiated planning treatment volume (PTV) are eligible as long as the prescription isovolume dose of any prior radiotherapy course is > 2.0cm distant from new lesion.
  • Inability to treat all oligometastatic sites with radiotherapy in the judgement of the investigator.
  • Intrapelvic lymph nodes as only site of prostate cancer recurrence.
  • Inability to swallow whole, undivided, unchewed, and uncrushed pills.
  • Known gastrointestinal disorder affecting oral medication absorption.
  • Co-morbidity defined as follows: Patients with any comorbidities that would prohibit completion of protocol specified therapy. Inflammatory Bowel Disease in patients in whom abdominopelvic radiotherapy is planned. History of congenital long QT syndrome; Current severe or unstable angina; New York Heart Association Functional Classification III/IV Heart Failure (Note: Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification.)
  • Other exclusion criteria may apply.

If you are interested in learning more about clinical trials, our clinical trial navigators can discuss your options and recommend opportunities that may be suitable for you. Call 813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form.